206 related articles for article (PubMed ID: 19339752)
1. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
Plowman-Prine EK; Okun MS; Sapienza CM; Shrivastav R; Fernandez HH; Foote KD; Ellis C; Rodriguez AD; Burkhead LM; Rosenbek JC
NeuroRehabilitation; 2009; 24(2):131-44. PubMed ID: 19339752
[TBL] [Abstract][Full Text] [Related]
2. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
Goberman AM
Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
[TBL] [Abstract][Full Text] [Related]
4. Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment.
D'Alatri L; Paludetti G; Contarino MF; Galla S; Marchese MR; Bentivoglio AR
J Voice; 2008 May; 22(3):365-72. PubMed ID: 17368837
[TBL] [Abstract][Full Text] [Related]
5. For better or worse: The effect of levodopa on speech in Parkinson's disease.
Ho AK; Bradshaw JL; Iansek R
Mov Disord; 2008 Mar; 23(4):574-80. PubMed ID: 18163453
[TBL] [Abstract][Full Text] [Related]
6. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
7. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P
Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
[TBL] [Abstract][Full Text] [Related]
9. [Speech and voice disorders in Parkinson's disease].
Martnez-Sánchez F
Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
[TBL] [Abstract][Full Text] [Related]
10. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
12. Prosody and levodopa in Parkinson's disease.
Azevedo LL; Reis CA; Souza IS; Cardoso FE
Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
[TBL] [Abstract][Full Text] [Related]
13. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease.
Gallena S; Smith PJ; Zeffiro T; Ludlow CL
J Speech Lang Hear Res; 2001 Dec; 44(6):1284-99. PubMed ID: 11776365
[TBL] [Abstract][Full Text] [Related]
14. [Parkinsonian dysarthria].
Gentil M; Pollak P; Perret J
Rev Neurol (Paris); 1995 Feb; 151(2):105-12. PubMed ID: 7676137
[TBL] [Abstract][Full Text] [Related]
15. Acoustic and perceptual consequences of articulatory rate change in Parkinson disease.
McRae PA; Tjaden K; Schoonings B
J Speech Lang Hear Res; 2002 Feb; 45(1):35-50. PubMed ID: 14748637
[TBL] [Abstract][Full Text] [Related]
16. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
Lechien JR; Blecic S; Ghosez Y; Huet K; Harmegnies B; Saussez S
J Voice; 2019 Sep; 33(5):716-720. PubMed ID: 29724466
[TBL] [Abstract][Full Text] [Related]
17. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
[TBL] [Abstract][Full Text] [Related]
18. Effect of bilateral stimulation of the subthalamic nucleus on different speech subsystems in patients with Parkinson's disease.
Pützer M; Barry WJ; Moringlane JR
Clin Linguist Phon; 2008 Dec; 22(12):957-73. PubMed ID: 19031193
[TBL] [Abstract][Full Text] [Related]
19. [Dysarthria across Parkinson's disease progression. Natural history of its components: dysphonia, dysprosody and dysarthria].
Pinto S; Ghio A; Teston B; Viallet F
Rev Neurol (Paris); 2010 Oct; 166(10):800-10. PubMed ID: 20800250
[TBL] [Abstract][Full Text] [Related]
20. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
Goberman AM; Coelho C
NeuroRehabilitation; 2002; 17(3):237-46. PubMed ID: 12237505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
